Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts.
https://t.co/MD6lU5oIvy
Dr. John Cush RheumNow
5 years 8 months ago
Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis--Takeuchi et al has published their extensive experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
https://t.co/hgMp5GcyFA https://t.co/Xdxg3v3wMm
Dr. John Cush RheumNow
5 years 8 months ago
Good reference Medical Research Council Manual Muscle scale (0-5)
0 No muscle activation
1 Trace muscle movt/twitch
2 Muscle movt w/o gravity
3 Movt against gravity
4 Movt against some resistance
5 Movt against full resistance, full range of motion
https://t.co/UVN6oHIL1L
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond.
Dr. John Cush RheumNow
5 years 8 months ago
Delays in Diagnosis of Axial Spondyloarthritis-Researchers found tht from 64 included studiesl, the mean diagnostic delay in axSpA patients was 6.7 years (95% CI 6.2, 7.2) with high levels of heterogeneity.
https://t.co/cOC1R264aC https://t.co/5UC7aip7j0
Dr. John Cush RheumNow
5 years 8 months ago
Hydroxychloroquine Shortage During COVID-19--According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.
https://t.co/h9hrAfv9xo https://t.co/IVSYCueK2h
Dr. John Cush RheumNow
5 years 8 months ago
2 yr Early RA cohort (CareRA) study found that RA pPatients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494).https://t.co/B1um1iMSKu
Dr. John Cush RheumNow
5 years 8 months ago
Born to Run (things) - the short inspirational start and career of Bruce Springsteen. https://t.co/Ki86v4viAj
Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts.
https://t.co/r5Cf4WS63s https://t.co/fEV77xMUye
Dr. John Cush RheumNow
5 years 8 months ago
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease.
Sponsored by Novartis Medical Affairs
Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts.
https://t.co/oGwmEXNaur https://t.co/S23cZw4Li1
The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).
Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.
This oopen-label, observational, cohort study from 275 sites in Japan, included 1355 systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) who were followed for 10 years and had at least 5 years of tacrolimus therapy.
Dr. John Cush RheumNow
5 years 8 months ago
Chinese SLE CSTAR study of 4792 SLE patients, of whom 374 (7.8%) had scarring alopecia. Risk factors for scarring alopecia included mucocutaneous lesions (OR 2.1) high SLICC/ACR-DI (OR 1.4), & positive Sm (OR 1.4), but less seen w/ renal CV involvement https://t.co/Y466WK3shS
